Stifel Rates Enliven Therapeutics (ELVN) buy, $80 Price Target

Stifel maintains its buy rating on Enliven Therapeutics with a price target of $80, a 57.64% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 11:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Stifel rated Enliven Therapeutics, Inc. ($ELVN) "buy" with a $80 price target on July 1, 2026.

Since the rating, $ELVN is up 4.2% after 1 week, up 12.4% after 1 month and down 23.5% to date (from the $48.76 close on Jul 1, 2026).

ELVN Enliven Therapeutics, Inc.

$37.32 +140.15% year to date

Daily close · Oct 16, 2026

Key Points

Stifel reiterated its buy rating on Enliven Therapeutics, setting a price target of $80.
Stifel's $80 price target implies 57.64% upside from Enliven Therapeutics, Inc.'s ($ELVN) current $50.75 share price.
Shares of NasdaqGS:ELVN traded near $50.75 on Wednesday, with a market cap of about $3.63 billion.
Institutional investors like Polar Capital Holdings increased their stake by 44.2% to 5,065,933 shares.

Get $ELVN trade alerts by text

We text you when insiders, Congress or big funds trade $ELVN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Enliven Therapeutics, Inc. alert may contain errors. Disclosures

Stifel has reiterated its buy rating on Enliven Therapeutics, Inc. (NasdaqGS:ELVN), maintaining a price target of $80. This update came on July 1, 2026, as shares of Enliven traded around $50.75.

Analyst rating track record

Stifel vs. the S&P 500

YTD return +46.32% hypothetical

All-time return +97.40% S&P 500 +28%

vs. S&P 500 +69.40% ahead of the index

Hypothetical returns from Stifel's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On July 1, 2026, Stifel maintained its buy rating on Enliven Therapeutics with a price target of $80. This follows a series of positive ratings; on June 29, 2026, Jones Trading also maintained a buy rating with a $70 target. Earlier, on June 9, 2026, Stifel initiated coverage with a buy rating and a $60 target.

Other Institutional Activity in Enliven Therapeutics

Several institutional investors have been active in Enliven Therapeutics. Polar Capital Holdings PLC increased its holdings by 1,552,253 shares, ending with 5,065,933 shares worth about $198.6 million, a 44.2% increase. Meanwhile, FMR LLC reduced its position by 278,389 shares to hold 6,829,246 shares valued at approximately $267.7 million, a 3.9% decrease. Commodore Capital LP cut its stake by 1,417,809 shares, ending with 3,275,000 shares worth $128.4 million, a 30.2% reduction.

Enliven Therapeutics, Inc. Stock Up 2.6%

Shares of Enliven Therapeutics traded near $50.75 on Wednesday. The company, with a market cap of about $3.63 billion, operates in the biotechnology sector. It has a beta of 0.396, indicating lower volatility compared to the market. The stock has seen a 52-week low of $14.79 and a high of $52.39, with moving averages of $42.22 (50-day) and $29.09 (200-day). Enliven has a strong current ratio of 40.318 and a quick ratio of 39.384, reflecting robust liquidity.

12-month forecast

$ELVN price target

Enliven Therapeutics, Inc. daily closes and this analyst's $80 target. Not advice.

Insider Buying and Selling at Enliven Therapeutics, Inc.

Recent insider transactions include OrbiMed Advisors LLC selling 860,123 shares on June 22, 2026. On June 17, 2026, CFO Benjamin Hohl sold 6,018 shares at an average price of $43.80 under a pre-planned 10b5-1 trading plan. Additionally, Chief Medical Officer Helen Louise Collins bought 5,000 shares at $2.48 and sold the same amount at $43.80 on the same day.

About Enliven Therapeutics

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boulder, Colorado. Founded in 2019, it focuses on developing small molecule inhibitors for cancer treatment. The company is advancing its clinical programs, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for non-small cell lung cancer.

Bottom Line

Stifel's reiteration of a buy rating with an $80 price target underscores continued confidence in Enliven Therapeutics' potential. Enliven's stock performance and institutional activity highlight its position in the biotech sector. Investors should note that these analyst opinions reflect past data and market conditions.